Expression of ras proto-oncogenes: Regulation and implications in the development of human tumors

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 2, 1997, Pages 65-75

  Zachos, G ^a,b   Spandidos, D A ^a,b  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ALTERNATIVE RNA SPLICING; CARCINOGENESIS; DNA METHYLATION; GENE EXPRESSION; HUMAN; ONCOGENE H RAS; ONCOGENE RAS; PROMOTER REGION; PROTO ONCOGENE; REVIEW; TRANSCRIPTION REGULATION; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MALE; NEOPLASMS; RAS PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0030855153     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00013-9     Document Type: Review

References (92)

1. Spandidos DA. The superfamily of ras-related genes. New York: Plenum Press, 1991:1-338.
2. Barbacid M. ras genes. Ann Rev Biochem 1987;56:779-827.
3. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993;62:851-91.
4. McGrath JP, Capon DJ, Smith DH, et al. Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 1983;304:501-6.
5. Cohen JB, Broz SD, Levinson AD. Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell 1989;58:461-72.
6. Spandidos DA, Holmes L. Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras1 gene. FEBS Lett 1987;218:41-6.
7. Cohen JB, Maureen VW, Levinson AD. A repetitive sequence element 3′ of the human c-Ha-ras1 gene has enhancer activity. J Cell Physiol (Suppl) 1987;5:75-81.
8. Willumsen BM, Christensen A. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984;310:583-6.
9. Abdellatif M, MacLellan WR, Schneider MD. p21 Ras as a governor of global gene expression. J Biol Chem 1994;269:15423-6.
10. Avruch J, Zhang X, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. TIBS 1994;19:279-83.
11. Marshall MS. Ras target proteins in eukaryotic cells. FASEB 1995;J 9:1311-8.
12. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
13. Kiaris H, Spandidos DA. Mutations of ras genes in human tumors (Review). Int J Oncol 1995;7:413-21.
14. Pulciani S, Santos E, Long LK, et al. ras gene amplification and malignant transformation. Mol Cell Biol 1985;5:2836-41.
15. Westaway D, Parkoff J, Moscovici C, et al. Identification of a provirally activated c-Ha-ras oncogene in an avian nephroblastoma via a novel procedure: cDNA cloning of a chimaeric viral-host transcript. EMBOJ 1986;5:301-9.
16. Spandidos DA. The human T24 H-ras1 oncogene: a study of the effects of overexpression of the mutated ras gene product in rodent cells. Anticancer Res 1986;6:259-62.
17. Egan SE, McClarty GA, Jarolim L, et al. Expression of H-ras correlates with metastatic potential: evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells. Mol Cell Biol 1987;7:830-7.
18. Tanaka T, Slamon DJ, Battifora H, et al. Expression of p21 Ras oncoproteins in human cancers. Cancer Res 1986;46:1465-70.
19. Spandidos DA, Wilkie NM. Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 1984;310:469-75.
20. Thorn JT, Todd AV, Warrilow D, et al. Characterization of the human N-ras promoter region. Oncogene 1991;6:1843-50.
21. Ishii S, Merlino GT, Pastan I. Promoter region of the human Harvey ras proto-oncogene: Similarity to the EGF receptor proto-oncogene promoter. Science 1985;230:1378-81.
22. Spandidos DA, Nichols RAB, Wilkie NM, et al. Phorbol ester-responsive H-ras1 gene promoter contains multiple TPA-inducible/ AP-1-binding consensus sequence elements. FEBS Lett 1988;240:191-5.
23. Ishii S, Kadonaga JT, Tjian R, et al. Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science 1986;232:1410-3.
24. Honkawa H, Masahashi W, Hashimoto S, et al. Identification of the principal promoter sequence of the c-Ha-ras transforming oncogene: deletion analysis of the 5′ flanking region by focus formation assay. Mol Cell Biol 1987;7:2933-40.
25. Lowndes NF, Paul J, Wu J, et al. c-Ha-ras gene bidirectional promoter expressed in vitro. Mol Cell Biol 1989;9:3758-70.
26. Jones KA, Kadonaga JT, Rosenfeld PJ, et al. A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication. Cell 1987;48:79-89.
27. Trimble WS, Hozumi N. Deletion analysis of the c-Ha-ras oncogene promoter. FEBS Lett 1987;219:70-4.
28. Nagase T, Ueno Y, Ishii S. Transcriptional control of the human Harvey ras proto-oncogene: role of multiple elements in the promoter region. Gene 1990;94:249-53.
29. Lee W, Keller EB. Regulatory elements mediating transcription of the human Ha-ras gene. J Mol Biol 1991;220:599-611.
30. Spandidos DA, Pintzas A. Differential potency and trans-activation of normal and mutant T24 human H-ras1 gene promoters. FEBS Lett 1988;232:269-74.
31. Pintzas A, Spandidos DA. Sp1 specific binding sites within the human H-ras promoter: potential role of the 6 bp deletion sequence in the T24 H-ras1 gene. Anticancer Res 1991;11:2067-70.
32. Spandidos DA, Zoumpourlis V, Zachos G, et al. Specific recognition of a transcriptional element within the human H-ras proto-oncogene by the p53 tumor suppressor. Int J Oncol 1995;7:1029-34.
33. Zoumpourlis V, Zachos G, Halazonetis TD, et al. Binding of wild-type and mutant forms of P53 protein from human tumors to a specific DNA sequence of the first intron of the H-ras oncogene. Int J Oncol 1995;7:1035-41.
34. Zachos G, Zoumpourlis V, Sekeris CE, et al. Binding of the glucocorticoid and estrogen receptors to the human H-ras oncogene sequences. Int J Oncol 1995;6:595-600.
35. Hashimoto-Gotoh T, Kikuno R, Takahashi M, et al. Possible role of the first intron of c-H-ras in gene expression: anti-cancer elements in oncogenes. Anticancer Res 1988;8:851-60.
36. Hashimoto-Gotoh T, Takahashi M, Kikuno R et al. Unusual sequence conservation in intron-1 of c-H-ras oncogene and its effect on p21 protein synthesis. In: Spandidos DA, editor. Current Perspectives of Molecular Cellular Oncology. London: JAI Press, 1992:211-230.
37. Trepicchio WL, Krontiris TG. Members of the rell NFKB family of transcriptional regulatory proteins bind the H-ras1 minisatelite DNA sequence. Nucleic Acids Res 1992;20:2427-34.
38. Jones PA. DNA methylation errors and cancer. Cancer Res 1996;56:2463-6.
39. Comb M, Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 1990;18:3975-82.
40. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991;64:1123-34.
41. Counts JL, Goodman JI. Comparative analysis of the methylation status of the 5′ flanking region of Ha-ras in B6C3F1, C3H/He and C57BL/6 mouse liver. Cancer Lett 1993;75:129-36.
42. Rachal MJ, Yoo H, Becker FF, et al. In vitro DNA cytosine methylation of cis-regulatory elements modulates c-Ha-ras promoter activity in vivo. Nucleic Acids Res 1989;17:5135-47.
43. Borello MG, Pierotti MA, Bongarzone I, et al. DNA methylation affecting the transforming activity of the human Ha-ras oncogene. Cancer Res 1987;47:7579.
44. Cohen JB, Levinson AD. A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature 1988;334:119-24.
45. Spandidos DA, Arvanitis D, Field JK. ras p21 expression in neuroblastomas and ganglio-neuroblastomas: correlation with patients' prognosis. Int J Oncol 1992;1:53-8.
46. Tanaka T, Slamon DJ, Shimoda H, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 1988;48:1030-4.
47. Kiaris H, Spandidos DA, Jones AS, et al. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous-cell carcinomas of the head and neck. Br J Cancer 1995;72:123-8.
48. Spandidos DA, Lamothe A, Field JK. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumors. Anticancer Res 1985;5:221-4.
49. Field J.K. Prognostic implications of ras oncogene expression in head and neck squamous cell carcinoma. In: DA Spandidos, editor. The superfamily of ras related genes. New York, Plenum Press, 1991:213-226.
50. Abdelatif OMA, Chandler FW, Mills LR, et al. Differential expression of c-myc and H-ras oncogenes in Barret's epithelium - a study using colorimetric in situ hybridazation. Arch Pathol Lab Med 1991;115:880-5.
51. Coredahl K, Caccon AC, Trobter M, et al. p53 and ras gene expression in human esophageal cancer and garret's epithelium - a prospective study. Cancer Detect Prev 1994;18:179-85.
52. Scambia G, Catozzi L, Benedetti-Panici P, et al. Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors. Br J Cancer 1994;69:995-9.
53. Kiaris H, Spandidos DA. Analysis of H-ras, K-ras and N-ras genes for expression, mutation and amplification in laryngeal tumours. Int J Oncol 1995;7:75-80.
54. Papadimitriou K, Yiagnisis M, Tolis G, et al. Immunohistochemical analysis of the ras oncogene protein in human thyroid neoplasms. Anticancer Res 1988;8:1223-8.
55. Miyamoto H, Harada M, Isobe H, et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991;51:6346-50.
56. Papadakis E, Malliri A, Linardopoulos S, et al. ras and p53 expression in non-small cell lung cancer patients: p53 overexpression correlates with a poor prognosis. Int J Oncol 1992;1:403-13.
57. Tiniakos D, Spandidos DA, Kakkanas A, et al. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res 1989;9:715-22.
58. Spandidos DA, Liloglou T, Arvanitis D, et al. ras gene activation in human small intestinal tumors. Int J Oncol 1993;2:513-8.
59. Karayiannis M, Yiagnisis M. Papadimitriou et al. Expression of the ras oncoprotein in gastric carcinomas and adjacent mucosa. Anticancer Res 1989;9:1505-10.
60. Motojima K, Furui J, Kohara N, et al. Expression of Kirstenras p21 in gastric-cancer correlates with tumor progression and is prognostic. Diagn Mol Pathol 1994;3:184-91.
61. Spandidos DA, Kerr IB. Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer 1994;49:681-8.
62. Miyahara M, Saito T, Kaketani K, et al. Clinical significance of Ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 1991;34:1097-102.
63. Spandidos DA, Karaiossifidi H, Malliri A, et al. Expression of Ras, Rb1 and p53 proteins in human breast cancer. Anticancer Res 1992;12:81-90.
64. Dati C, Muraca R, Tazartes O, et al. c-ErbB-2 and Ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 1991;47:833-8.
65. Spandidos DA, Agnantis NJ. Human malignant tumors of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res 1984;4:269-72.
66. Bland KI, Konstandoulakis MM, Vezeridis MP, et al. Oncogene protein coexpression. Value of Ha-ras, c-myc, c-fos and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995;221:706-18.
67. Zhang PL, Galaf D, Russo J. Allele loss and point mutation in codons 12 and 61 of the c-Ha-ras oncogene in carcinogen-transformed human breast epithelial cells. Mol Carcinog 1994;9:46-56.
68. Nakanishi H, Taylor RM, Hawkins AL, et al. Establishment of hormone-dependent and hormone-independent carcinoma cell lines with different metastatic potentials from spontaneous mammary tumors in aged Wistar rats. Int J Cancer 1994;58:592-601.
69. Janes PW, Daly RJ, deFazio A, et al. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994;9:3601-8.
70. Vageli D, Kiaris H, Delakas D, et al. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 1996;107:241-7.
71. Ting-jie M, Ze W, Nianli S. Correlation between the expression of the p21 ras oncogene product and the biological behavior of bladder tumors. Eur Urol 1991;20:307-10.
72. Long CA, O'Brien TJ, Sanders MM, et al. ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;159:1512-6.
73. Scambia G, Catozzi L, Panici PB. et al. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone and epidermal growth factor. Am J Obstet Gynecol 1993;168:71-8.
74. Katsaros D, Theillet C, Zola P, et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res 1995;15:1501-10.
75. Gougopoulou DM, Kiaris H, Ergazaki M, et al. Mutations and expression of the ras family genes in leukemias. Stem Cells 1996;14:725-9.
76. Hyder SM, Stancel GM, Loose-Mitchell DS. Steroid hormoneinduced expression of oncogene encoded nuclear proteins. Crit Rev Eucaryot Gene Exp 1995;4:55-116.
77. Zachos G, Varras M, Koffa M, et al. The association of the H-ras oncogene and steroid hormone receptors in gynecological cancer. J Exp Ther Oncol 1996;1:335-41.
78. Zachos G, Varras M, Koffa M, et al. Glucocorticoid and estrogen receptors have elevated activity in human endometrial and ovarian tumors as compared to the adjacent normal tissues and recognize sequence elements of the H-ras proto-oncogene. Jpn J Cancer Res 1996;87:916-22.
79. Telang NT, Narayanan R, Bradlow HL, et al. Coordinated expression of intermediate biomarkers for tumorigenic transformation in ras-transfected mouse mammary epithelial cells. Breast Cancer Res Treat 1991;18:155-63.
80. Suto A, Bradlow HL, Wong GY, et al. Persistent estrogen responsiveness of ras oncogene-transformed mouse mammary epithelial cells. Steroids 1992;57:262-8.
81. Easton D, Ford D, Bishop D, et al. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:265-71.
82. Phelan CM, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996;12:309-11.
83. Kashani-Sabet M, Funato T, Florenes VA, et al. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-2.
84. Feng M, Cabrera G, Deshane J, et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995;55:2024-8.
85. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 1993;261:1004-12.
86. Monia BP, Johnston JF, Eckers DJ, et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992;267:19954-62.
87. Schwab G, Chavany C, Duroux I, et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras -mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 1994;91:10460-4.
88. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.
89. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
90. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant Ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding Ras mutation. Lancet 1995;346:1399-400.
91. Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo Ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;65:450-3.
92. Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996;93:7855-60.